Otwarty dostęp

Circumventing vascular barriers for effective immunotherapy in brain tumors – focus on glioblastoma

  
06 sie 2025

Zacytuj
Pobierz okładkę

Figure 1.

Targeting the immune-vascular interface in glioblastoma. The combined effect of blood-brain barrier (BBB), blood-tumor barrier (BTB), and endothelial anergy contributes to the exclusion of immune cells (T, NK) from the brain tumor microenvironment. Overcoming this scarcity by intracranial delivery of immune cells, modulating vascular wall (para-endothelial gaps), coupled with tumor debulking (to reduce the size of the target cell population) and targeting immunosuppressive mechanisms may collectively improve outcomes of immunotherapy in glioblastoma and other brain tumors (see text)
Targeting the immune-vascular interface in glioblastoma. The combined effect of blood-brain barrier (BBB), blood-tumor barrier (BTB), and endothelial anergy contributes to the exclusion of immune cells (T, NK) from the brain tumor microenvironment. Overcoming this scarcity by intracranial delivery of immune cells, modulating vascular wall (para-endothelial gaps), coupled with tumor debulking (to reduce the size of the target cell population) and targeting immunosuppressive mechanisms may collectively improve outcomes of immunotherapy in glioblastoma and other brain tumors (see text)
Język:
Angielski